HCP
CORT icon

Hexagon Capital Partners’s Corcept Therapeutics CORT Stock Holding History

Hexagon Capital Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-394
Closed -$45K – 409
2025
Q1 		$45K Hold
394
– – 0.01% 498
2024
Q4 		$19.9K Sell
394
-204
-34% -$10.7K ﹤0.01% 790
2024
Q3 		$27.7K Hold
598
– – 0.01% 596
2024
Q2 		$19.4K Buy
598
+222
+59% +$6.08K ﹤0.01% 694
2024
Q1 		$9.47K Buy
+376
New +$8.88K ﹤0.01% 868

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Hexagon Capital Partners's CORT Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 394 shares — an estimated $45K sold.

Hexagon Capital Partners first reported a position in CORT in Q1 2024 and held it in 5 quarters. The position peaked at $45K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 394 Corcept Therapeutics shares in Q2 2025, an estimated $45K.
  • Hexagon Capital Partners first reported a position in Corcept Therapeutics in Q1 2024 and held it in 5 quarters.
  • Hexagon Capital Partners's Corcept Therapeutics position peaked at $45K in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.